Marizyme, Inc. (MRZM)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
-0.0078 (-96.30%)
At close: Apr 14, 2025
Marizyme Revenue
Marizyme had revenue of $183.42K in the twelve months ending September 30, 2024, down -68.96% year-over-year. In the year 2023, Marizyme had annual revenue of $645.81K with 176.60% growth.
Revenue (ttm)
183.42K
Revenue Growth
-68.96%
P/S Ratio
0.22
Revenue / Employee
14.11K
Employees
13
Market Cap
39.54K
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Marizyme News
- 1 year ago - Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - GlobeNewsWire
- 1 year ago - Marizyme CEO Delivers Business Update - GlobeNewsWire
- 1 year ago - Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ - GlobeNewsWire
- 2 years ago - Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products - GlobeNewsWire
- 3 years ago - Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office - GlobeNewsWire
- 3 years ago - Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing - GlobeNewsWire
- 3 years ago - Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress - GlobeNewsWire
- 3 years ago - Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories - GlobeNewsWire